These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 8148238)
1. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms. Chen Z; Rosten SI; Lord EM; Gaspari AA Reg Immunol; 1993; 5(5):285-92. PubMed ID: 8148238 [TBL] [Abstract][Full Text] [Related]
2. Minor histocompatibility antigen-dependent rejection of Pam 212 epidermoid carcinoma by DBA/2 mice. Chen Z; Knepper JE; Gaspari AA Cell Immunol; 1995 Aug; 164(1):90-9. PubMed ID: 7543374 [TBL] [Abstract][Full Text] [Related]
3. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. Chen PW; Ananthaswamy HN J Immunol; 1993 Jul; 151(1):244-55. PubMed ID: 8326126 [TBL] [Abstract][Full Text] [Related]
4. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft. Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758 [TBL] [Abstract][Full Text] [Related]
5. H-2 antigens and tumour-associated transplantation antigens in clones derived from a methylcholanthrene-induced BALB/c tumour: their influence on the generation in vitro and in vivo of the specific anti-tumour immune response. Pérez M; Garrido A; Algarra I; Caballero A; Delgado C; Collado MD; Fernández-Cruz E; Garrido F Exp Clin Immunogenet; 1989; 6(3):204-18. PubMed ID: 2631798 [TBL] [Abstract][Full Text] [Related]
6. Immune selection in murine tumors. Ph.d thesis. Svane IM; Engel AM APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251 [TBL] [Abstract][Full Text] [Related]
7. Reduced tumorigenicity of murine tumor cells secreting gamma-interferon is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Esumi N; Hunt B; Itaya T; Frost P Cancer Res; 1991 Feb; 51(4):1185-9. PubMed ID: 1900037 [TBL] [Abstract][Full Text] [Related]
8. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Lee HM; Timme TL; Thompson TC Cancer Res; 2000 Apr; 60(7):1927-33. PubMed ID: 10766182 [TBL] [Abstract][Full Text] [Related]
9. Apparent split tolerance of CD8+ T cells from beta 2-microglobulin-deficient (beta 2m-/-) mice to syngeneic beta 2m+/+ cells. Jhaver KG; Rao TD; Frey AB; Vukmanović S J Immunol; 1995 Jun; 154(12):6252-61. PubMed ID: 7759863 [TBL] [Abstract][Full Text] [Related]
11. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. Merritt RE; Yamada RE; Crystal RG; Korst RJ J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342 [TBL] [Abstract][Full Text] [Related]
12. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo. Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570 [TBL] [Abstract][Full Text] [Related]
13. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck. Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824 [TBL] [Abstract][Full Text] [Related]
14. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors. Schirmbeck R; Böhm W; Reimann J J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655 [TBL] [Abstract][Full Text] [Related]
15. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Koeppen H; Acena M; Drolet A; Rowley DA; Schreiber H Eur J Immunol; 1993 Nov; 23(11):2770-6. PubMed ID: 8223853 [TBL] [Abstract][Full Text] [Related]
16. [Immunobiological characterization of murine LB leukemia and the LBC cell line]. Hajos SE; Mongini C; Waldner C; Sánchez Lockhart M; Gravisaco MJ; Roig I; Fernańdez T; Alvarez E Medicina (B Aires); 1996; 56 Suppl 1():45-56. PubMed ID: 9224974 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-gamma are cytolytic in vitro and tumoricidal in vivo. Xiang J; Moyana T Cancer Gene Ther; 1998; 5(5):313-20. PubMed ID: 9824051 [TBL] [Abstract][Full Text] [Related]
18. Interactions between autologous CD4+ and CD8+ T lymphocytes and human squamous cell carcinoma of the head and neck. Okada K; Yasumura S; Muller-Fleckenstein I; Fleckenstein B; Talib S; Koldovsky U; Whiteside TL Cell Immunol; 1997 Apr; 177(1):35-48. PubMed ID: 9140094 [TBL] [Abstract][Full Text] [Related]
19. Immune response to somatic cell hybrids between ultraviolet radiation-induced regressor and spontaneous progressor C3H mouse tumor cells. Chen PW; Kaba DS; Ananthaswamy HN Cancer Res; 1990 Mar; 50(5):1544-9. PubMed ID: 2137370 [TBL] [Abstract][Full Text] [Related]
20. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL. Bakker AB; Phillips JH; Figdor CG; Lanier LL J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]